CD79B and diffuse large B-cell lymphoma: EBV+ DLBCL cases also exhibit a genetic profile different from EBV-negative DLBCL, characterized by frequent mutations in TET2 and DNMT3A and infrequent mutations in CD79B, MYD88, CDKN2A, and FAS [87].